Neurocrine Biosciences
NBIX
NBIX
244 hedge funds and large institutions have $4.32B invested in Neurocrine Biosciences in 2016 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 85 increasing their positions, 88 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
244
Holders Change
+13
Holders Change %
+5.63%
% of All Funds
6.52%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.19%
New
39
Increased
85
Reduced
88
Closed
24
Calls
$39.2M
Puts
$8.02M
Net Calls
+$31.2M
Net Calls Change
-$37.8M
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
$131M |
| 2 |
Bank of New York Mellon
New York
|
$71.2M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
$45.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
$102M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
$658M |
Top Sellers
| 1 |
Millennium Management
New York
|
$5.47M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
$1.83M |
| 3 |
HM
HealthCor Management
New York
|
$0 |
| 4 |
PA
Perceptive Advisors
New York
|
$125M |
| 5 |
CCM
Cadian Capital Management
New York
|
$1.62M |
